SDHB and triple-negative breast carcinoma: Glutaminase inhibitor CB-839 was tested on SDH-deficient GISTs, SDH-deficient non-GIST tumors, triple-negative breast cancer, and others for their interactions with CB-839 and standard chemotherapy (NCT02071862).